National Pharmaceutical Pricing Authority (NPPA) vide order dated January 16, 2018 has fixed the ceiling prices of various drugs under the Drugs (Prices Control) Order, 2013 such as:
· Amphotericin B - Lipid/ Liposomal
All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price
All the existing manufacturers having MRP lower than the ceiling price shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013
The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price
The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers
The manufacturers shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
[F. No. 8(52)/2017/D.P./NPPA-Div.-II]